Budget Impact Analysis of Panobinostat – Bortezomib and Dexamethasone, As 3rd Or 4th Line of Treatment in Patients with Relapsed/Refractory Multiple Myeloma in Greece
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2189
https://www.valueinhealthjournal.com/article/S1098-3015(16)33555-0/fulltext
Title :
Budget Impact Analysis of Panobinostat – Bortezomib and Dexamethasone, As 3rd Or 4th Line of Treatment in Patients with Relapsed/Refractory Multiple Myeloma in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33555-0&doi=10.1016/j.jval.2016.09.2189
First page :
A729
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2078